+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cough Hypersensitivity Syndrome Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 5012620
  • Report
  • April 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • ASTRAZENECA
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc.
  • Johnson & Johnson Inc
  • Merck & Co., Inc.
  • MORE
The global cough hypersensitivity syndrome treatment market size is expected to grow at a CAGR of 5.5% over the forecast period. The market is projected to exhibit moderate growth over the forecast period, which can be attributed to factors such as humid climate, unhealthy lifestyle, and rising disease incidence.

Cough is a common disease condition, affecting millions of people worldwide. The rise in the prevalence of chronic respiratory diseases across the globe is leading to an increase in chronic cough conditions globally. Thus, the growing disease burden offers a promising future for the global market. Although some studies suggest that the risk of developing cough may be increased due to other certain factors such as asthma, smoking, hot and humid climate, and viral or bacterial infection can trigger the condition.

As per the WHO, cough condition is ranked as the most prevalent disease across the globe. Most of the novel products are reformulated drugs with improvised vehicles or combinatorial therapies. The treatment algorithm is witnessing a paradigm shift from small molecules towards natural therapies and biologics. Combination therapies have also been gaining popularity over the last few years. Most industry-sponsored products are in clinical trials.

In addition, key players are focusing on making cough syrup of pleasant taste and easy intake for oral use. The growing disease burden includes majority of pediatric population as they have lower immunity level compared to adults. Most pediatric patients prefer liquid as dosage forms. Growing demand of cough remedies is driven by the presence of routinely monitored formulations, technological advancement in the field of drug delivery systems, and increasing awareness amongst patients. However, drug abuse and dependency of cough hypersensitivity syndrome drugs may restrict the market growth.

Key Market Trends

The Retail Pharmacy From Distribution Channel Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period
  • The retail pharmacy segment dominated the market owing to due to easy availability and accessibility of these pharmacies. For instance, MedPlus has around 1650 outlets out of which 1,350 are self-owned and rest are taken as a franchisee. Retailers provide discounts on bulk purchases, offer quick delivery, and always have sufficient product stock, owing to which consumers opt for these distribution channels.
  • Moreover, online pharmacy is estimated to be the fastest-growing segment over the forecast period. The convenience of delivering the medicines at the doorstep is the major advantage of online pharmacy. The discounted price that the online pharmacies provide is also a factor that drives market growth. As per an estimate, there are between 30,000 and 50,000 online pharmacies operating in the USA, making online pharmacies a leading segment.
The North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America is leading owing to the presence of major market players. Several collaborative efforts were undertaken by major companies to enhance their R&D capabilities and ensure high medical standards are anticipated to impel the demand across this region. Moreover, the majority share can also be attributed to the high disease burden in this region. Increasing cases of cough and rising pediatric population are the key factors that are driving the market studied in this region.

The Asia-Pacific is expected to witness the fastest growth over the forecast period. Strategic partnerships between pharmaceutical companies and government organizations are on a rise in the region, particularly to develop generic drugs and spread awareness amongst healthcare professionals. Increasing awareness levels and rising focus of healthcare providers on the eradication of coughing ailments are expected to boost growth within the region. This makes the Asia pacific market highly lucrative.

Competitive Landscape

The market for cough hypersensitivity syndrome treatment is highly competitive and consists of several global as well as local players. Investment for the development of effective & long-acting products with lesser adverse effects and improving geographic penetration through partnerships and collaborations are the key strategies adopted by the companies to increase their market share. The major players include companies such as Johnson & Johnson, Bayer AG, GlaxoSmithKline plc, Pfizer, Novartis, AstraZeneca, and Teva Canada Limited.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ASTRAZENECA
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc.
  • Johnson & Johnson Inc
  • Merck & Co., Inc.
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expanding Target Audience
4.2.2 Robust Pipeline & Introduction of Novel Therapies
4.2.3 Increasing Government Initiatives
4.3 Market Restraints
4.3.1 Drug Abuse and Dependency
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Antitussive Agents
5.1.2 Inhaled Corticosteroids (ICS)
5.1.3 Short Acting Beta2-Agonists (SABA)
5.1.4 Anti-cholinergics
5.1.5 Antihistamines
5.1.6 Proton Pump Inhibitors
5.1.7 Others
5.2 By End User
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ASTRAZENECA
6.1.2 Bayer AG
6.1.3 Boehringer Ingelheim GmbH
6.1.4 GlaxoSmithKline plc.
6.1.5 Johnson & Johnson Inc
6.1.6 Merck & Co., Inc.
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Teva Canada Limited
6.1.10 Vertex Pharmaceuticals Incorporated

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ASTRAZENECA
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc.
  • Johnson & Johnson Inc
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Teva Canada Limited
  • Vertex Pharmaceuticals Incorporated
Note: Product cover images may vary from those shown
Adroll
adroll